Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/74920
Title:
Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer.
Authors:
Howell, Anthony ( 0000-0002-3879-5991 ) ; Locker, Gershon
Abstract:
The widespread use of tamoxifen has led to significant improvements in survival for postmenopausal women with early-stage hormone receptor-positive breast cancer; however, approximately 30% of patients die despite receiving tamoxifen as adjuvant treatment. In addition, concerns exist regarding tamoxifen-associated side effects, including endometrial cancer and thromboembolic disease. The development of the third-generation aromatase inhibitors (AIs; anastrozole, exemestane, and letrozole) therefore represented a welcome potential alternative to tamoxifen. Several clinical trials have demonstrated the superiority of AIs over tamoxifen in the adjuvant treatment of postmenopausal women with hormone-sensitive breast cancer, but these trials differ in their design and in the characteristics of their patient populations. This review discusses the different designs of the primary adjuvant, switching, extended adjuvant, and sequencing trials that are investigating the use of AIs in the adjuvant treatment of breast cancer and provides direction regarding how the data from these trials could be used to guide treatment choice. This review also demonstrates why one should not extrapolate results from clinical trials to clinical situations that differ from the clinical trial or from clinical trials investigating a particular AI to clinical situations involving another AI.
Affiliation:
Cancer Research UK, Christie Hospital NHS Trust, University of Manchester, UK.
Citation:
Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer. 2005, 6 (4):302-9 Clin. Breast Cancer
Journal:
Clinical Breast Cancer
Issue Date:
Oct-2005
URI:
http://hdl.handle.net/10541/74920
PubMed ID:
16277879
Type:
Article
Language:
en
ISSN:
1526-8209
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHowell, Anthony-
dc.contributor.authorLocker, Gershon-
dc.date.accessioned2009-07-22T10:23:12Z-
dc.date.available2009-07-22T10:23:12Z-
dc.date.issued2005-10-
dc.identifier.citationDefining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer. 2005, 6 (4):302-9 Clin. Breast Canceren
dc.identifier.issn1526-8209-
dc.identifier.pmid16277879-
dc.identifier.urihttp://hdl.handle.net/10541/74920-
dc.description.abstractThe widespread use of tamoxifen has led to significant improvements in survival for postmenopausal women with early-stage hormone receptor-positive breast cancer; however, approximately 30% of patients die despite receiving tamoxifen as adjuvant treatment. In addition, concerns exist regarding tamoxifen-associated side effects, including endometrial cancer and thromboembolic disease. The development of the third-generation aromatase inhibitors (AIs; anastrozole, exemestane, and letrozole) therefore represented a welcome potential alternative to tamoxifen. Several clinical trials have demonstrated the superiority of AIs over tamoxifen in the adjuvant treatment of postmenopausal women with hormone-sensitive breast cancer, but these trials differ in their design and in the characteristics of their patient populations. This review discusses the different designs of the primary adjuvant, switching, extended adjuvant, and sequencing trials that are investigating the use of AIs in the adjuvant treatment of breast cancer and provides direction regarding how the data from these trials could be used to guide treatment choice. This review also demonstrates why one should not extrapolate results from clinical trials to clinical situations that differ from the clinical trial or from clinical trials investigating a particular AI to clinical situations involving another AI.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectCancer Stagingen
dc.subject.meshAndrostadienes-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshAromatase Inhibitors-
dc.subject.meshBreast Neoplasms-
dc.subject.meshChemotherapy, Adjuvant-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshNeoplasm Staging-
dc.subject.meshNitriles-
dc.subject.meshResearch Design-
dc.subject.meshTamoxifen-
dc.subject.meshTriazoles-
dc.titleDefining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK, Christie Hospital NHS Trust, University of Manchester, UK.en
dc.identifier.journalClinical Breast Canceren
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.